TC
AKBA icon

TFS Capital’s Akebia Therapeutics AKBA Stock Holding History

TFS Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-90,854
Closed -$836K – 608
2017
Q1 		$836K Buy
+90,854
New +$887K 0.27% 125
2016
Q3 		– Sell
-173,312
Closed -$1.3M – 735
2016
Q2 		$1.3M Buy
+173,312
New +$1.51M 0.24% 106
2016
Q1 		– Sell
-11,231
Closed -$145K – 986
2015
Q4 		$145K Buy
+11,231
New +$115K 0.02% 617
2015
Q3 		– Sell
-21,604
Closed -$222K – 880
2015
Q2 		$222K Buy
+21,604
New +$184K 0.02% 731
2015
Q1 		– Sell
-14,703
Closed -$171K – 940
2014
Q4 		$171K Sell
14,703
-6,980
-32% -$100K 0.02% 843
2014
Q3 		$480K Buy
+21,683
New +$498K 0.04% 610

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TFS Capital's AKBA Position: Q2 2017 in Review

TFS Capital sold out of Akebia Therapeutics (AKBA) in Q2 2017, closing a stake of 90,854 shares — an estimated $836K sold.

TFS Capital first reported a position in AKBA in Q3 2014 and held it in 6 quarters. The position peaked at $1.3M in Q2 2016. 118 funds tracked by Wall St. Rank hold AKBA as of Q2 2017.

  • TFS Capital reported no remaining Akebia Therapeutics position as of Q2 2017 after selling out during the quarter.
  • TFS Capital sold 90,854 Akebia Therapeutics shares in Q2 2017, an estimated $836K.
  • TFS Capital first reported a position in Akebia Therapeutics in Q3 2014 and held it in 6 quarters.
  • TFS Capital's Akebia Therapeutics position peaked at $1.3M in Q2 2016.
  • 118 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.